Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-β

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2583-2594

  Mele, Valentina ^a,b   Muraro, Manuele G ^a   Calabrese, Diego ^b   Pfaff, Dennis ^b   Amatruda, Nunzia ^a,c   Amicarella, Francesca ^a   Kvinlaug, Brynn ^a   Bocelli Tyndall, Chiara ^b   Martin, Ivan ^a   Resink, Therese J ^b   Heberer, Michael ^a   Oertli, Daniel ^a   Terracciano, Luigi ^b   Spagnoli, Giulio C ^a   Iezzi, Giandomenica ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

colorectal cancer; EMT; MSC; surface bound TGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL CONTACT; CELL PROLIFERATION; CELL STRUCTURE; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR VOLUME; UPREGULATION;

COLORECTAL CANCER; EMT; MSC; SURFACE-BOUND TGF-Β;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; CADHERINS; CELL ADHESION; CELL COMMUNICATION; CELL MEMBRANE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINES; COLORECTAL NEOPLASMS; CYTOKINES; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84896390483     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28598     Document Type: Article

References (46)

1. Bianco P, Robey PG, Simmons PJ,. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008; 2: 313-9.
2. Chamberlain G, Fox J, Ashton B, et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-49.
3. Uccelli A, Moretta L, Pistoia V,. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-36.
4. Hall B, Andreeff M, Marini F,. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 2007: 263-83.
5. Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009; 27: 2614-23.
6. Lazennec G, Jorgensen C,. Concise review: adult multipotent stromal cells and cancer: risk or benefit Stem Cells 2008; 26: 1387-94.
7. Bexell D, Scheding S, Bengzon J,. Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 2010; 18: 1067-75.
8. Dwyer RM, Kerin MJ,. Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets Hum Gene Ther 2010; 21: 1506-12.
9. De Boeck A, Pauwels P, Hensen K, et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut 2013; 62: 550-60.
10. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-44.
11. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-63.
12. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203: 1235-47.
13. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48.
14. Otsu K, Das S, Houser SD, et al. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009; 113: 4197-205.
15. Shinagawa K, Kitadai Y, Tanaka M, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010; 127: 2323-33.
16. Tsai KS, Yang SH, Lei YP, et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 2011; 141: 1046-56.
17. Zhu Y, Sun Z, Han Q, et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009; 23: 925-33.
18. Klopp AH, Gupta A, Spaeth E, et al. Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth Stem Cells 2010; 29: 11-9.
19. Kucerova L, Matuskova M, Hlubinova K, et al. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010; 9: 129.
20. Lin G, Yang R, Banie L, et al. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 2010; 70: 1066-73.
21. Liu Y, Han ZP, Zhang SS, et al. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem 2011; 286: 25007-15.
22. Li HJ, Reinhardt F, Herschman HR, et al. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2012; 2: 840-55.
23. Mishra PJ, Mishra PJ, Humeniuk R, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68: 4331-9.
24. Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4: e4992.
25. Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257-72.
26. Jing Y, Han Z, Liu Y, et al. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS One 2012; 7: e43272.
27. Martin FT, Dwyer RM, Kelly J, et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 2010; 124: 317-26.
28. Polyak K, Weinberg RA,. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-73.
29. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
30. Bastid J,. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev 2012; 31: 277-83.
31. Brabletz T, Hlubek F, Spaderna S, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179: 56-65.
32. Huang WH, Chang MC, Tsai KS, et al. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2013; 32: 4343-54.
33. Bocelli-Tyndall C, Zajac P, Di Maggio N, et al. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 2010; 62: 3815-25.
34. Di Maggio N, Mehrkens A, Papadimitropoulos A,. Fibroblast growth factor-2 maintains a niche-dependent population of self-renewing highly potent non-adherent mesenchymal progenitors through FGFR2c. Stem Cells 2012; 30: 1455-64.
35. Albini A, Benelli R,. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007; 2: 504-11.
36. Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010; 103: 382-90.
37. Joshi MB, Philippova M, Ivanov D, et al. T-cadherin protects endothelial cells from oxidative stress-induced apoptosis. FASEB J 2005; 19: 1737-9.
38. Caceres G, Zhu XY, Jiao JA, et al. Imaging of luciferase and GFP-transfected human tumours in nude mice. Luminescence 2003; 18: 218-23.
39. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436: 123-7.
40. Nakamura K, Kitani A, Strober W,. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-44.
41. Wipff PJ, Hinz B,. Integrins and the activation of latent transforming growth factor beta1-an intimate relationship. Eur J Cell Biol 2008; 87: 601-15.
42. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-8.
43. Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, et al. Type III TGF-beta receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia 2011; 13: 758-70.
44. Paschos KA, Canovas D, Bird NC,. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 2009; 21: 665-74.
45. Minoo P, Baker K, Baumhoer D, et al. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol 2010; 41: 70-8.
46. Karamitopoulou E, Zlobec I, Patsouris E, et al. Loss of E-cadherin independently predicts the lymph node status in colorectal cancer. Pathology 2011; 43: 133-7.